IQVIA Holdings stock
Price history
+20.26% over the period1 year: from $216.12 (November 17, 2025) to $259.91 (November 17, 2026), +20.26%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $259.91 |
| October 30, 2026 | $267.33 |
| September 30, 2026 | $268.85 |
| August 31, 2026 | $261.19 |
| July 31, 2026 | $235.02 |
| June 30, 2026 | $193.22 |
| May 29, 2026 | $182.21 |
| April 30, 2026 | $158.37 |
| March 31, 2026 | $170.54 |
| February 27, 2026 | $178.81 |
| January 30, 2026 | $230.15 |
| December 31, 2025 | $225.41 |
| November 28, 2025 | $230.01 |
| November 17, 2025 | $216.12 |
At a glance
The company
Provides clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries
Latest results
Quarter to September 30, 2026 · EPS $3.34 (estimate $3.25)
TickerLandia's take on IQVIA Holdings
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 33 vs a median of 46 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 31 vs 34 (−9%) in a group of 9.
- Strong point: Market momentum (81/100 in its group). Weak point: Financial strength (9/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−9.46% from the 52-week high
Analysts · 20 analysts
Average target$311.89+21.07% vs. price
Buy 18 · Hold 2 · Sell 0 · Strong buy
TickerLandia Fingerprint: IQVIA Holdings
Compared with similar companies: very low financial strength and very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage43
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 31.5 44 Forward P/E 18.2 27 EV/EBITDA 18.5 44 Price/book 6.40 67 Price/sales 2.46 35 Profitabilityaverage40
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 13.9% 24 Gross margin 33.1% 24 Net margin 8.1% 43 ROA 5.1% 35 ROE 21.4% 75 Earnings stabilityhigh72
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.6% 83 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthaverage46
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +8.00% 39 Average revenue growth (3 years) +4.21% 61 Earnings growth (year over year) +8.80% 37 Financial strengthvery low9
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 4.88 2 Debt/equitycounts in reverse: lower means more financial strength 2.40 6 Current ratio 0.83 6 Interest coverage 3.15 21 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong81
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +11.51% 77 Relative strength (6 months) +52.15% 96 1-year return +19.19% 60 Distance from 200-day average +21.89% 93 Riskaverage48
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 35.9% 65 Volatility (60 days) 26.8% 28 Beta (1 year) 0.70 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
IQVIA Holdings is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), IQVIA Holdings's P/E today is 33.2, below the median of its last 10 fiscal years (46.4; between 17.1 and 161.8 from 2016 to 2025). IQVIA Holdings's P/E (trailing 12 months): 31.5, −9% against the median of a group of 9 similar companies (34.5).
Compared with 9 similar companies
| Metric | IQVIA Holdings | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 31.5 | Middle | |
| Forward P/E | 18.2 | Low | |
| Operating margin | 13.9% | Middle | |
| ROE | 21.4% | Middle | |
| Debt/equity | 2.40 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: IQVIA Holdings. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$4.43B
Latest quarter · Q3 2026
Net income
$350M
Latest quarter · Q3 2026
Quarterly net margin
7.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $42.63B
- P/E
- 31.5
- EPS
- $8.22
- Volume
- 983.59K
- Daily trading
- €366.92M
- Dividend yield
- 0.00%
How IQVIA Holdings is changing
All resultsRevenue grew 7.5% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 138% of net income
Shares outstanding down 11.0% in 5 years
Returns
IQVIA Holdings returns
$1,000 invested in IQVIA Holdings 5 years ago, on November 17, 2021, would be worth $983 today: −1.72% in total, −0.35% per year. This is the price return only: dividends are excluded.
| Period | IQVIA Holdings | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −2.25% | −3.17% | $978 |
| 6 months | +52.32% | +0.11% | $1,523 |
| Year to date | +15.31% | +8.34% | $1,153 |
| 1 year | +20.26% | +11.15% | $1,203 |
| 3 years | +26.92% | +64.30% | $1,269 |
| 5 years | −1.72% | +58.18% | $983 |
| 10 years | +227.01% | +239.10% | $3,270 |
Over the last 6 months it has done better than 89% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
IQVIA Holdings: technical analysis
IQVIA Holdings shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 8.8% below its all-time closing high ($282.61, December 30, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 40
- Between 30 and 70
- vs 200-session average
- +21.89%
Support and resistance
Price areas where IQVIA Holdings has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$274.49+6.56%3 touches, last on October 6, 2026
- Last price$257.60
- Support$252.21−2.09%4 touches, last on November 3, 2026
- Support$245.61−4.66%2 touches, last on January 27, 2026
- Support$234.03−9.15%2 touches, last on August 17, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.70
- Volatility (60 sessions, annualised)
- 26.8%
- Largest fall in the last year
- −35.87%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
IQVIA Holdings: seasonality
Average monthly price change over 14 years
Over the last 14 years, the strongest month for IQVIA Holdings has been July: +9.67% on average, positive in 12 years out of 14. The weakest has been September: −3.04% on average, positive in 4 years out of 14. November, the current month, has been positive in 9 years out of 13 (+3.68% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.45% | +2.47% | 9 of 13 |
| February | +0.07% | −1.40% | 6 of 13 |
| March | −2.18% | +0.18% | 7 of 13 |
| April | +0.86% | −3.44% | 4 of 13 |
| May | +2.04% | +2.56% | 8 of 13 |
| June | +3.57% | +2.22% | 10 of 14 |
| July | +9.67% | +8.19% | 12 of 14 |
| August | +1.09% | +2.16% | 8 of 14 |
| September | −3.04% | −2.36% | 4 of 14 |
| October | −0.12% | −2.81% | 5 of 14 |
| November | +3.68% | +2.86% | 9 of 13 |
| December | +1.27% | +0.99% | 7 of 13 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
IQVIA Holdings and its competitors
Based in Durham, North Carolina, and in existence since 1982, IQVIA Holdings Inc. serves drug developers, biotechnology firms, device makers and consumer health companies with data, analytics and research services. Its activities include cloud-based software for commercial teams, real-world evidence studies, consulting on advanced analytics, clinical trial management, central laboratory and genomic testing, and contract sales with medical affairs support. Customers are located in the Americas, Europe, Africa and the Asia-Pacific region. A biosimilar development collaboration with Kexing Biopharm is also part of its work.
- Headquarters
- Durham, United States
- Employees
- 95,000
- Founded
- 1982
- Chief executive
- Ari Bousbib
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| IQVIA HoldingsIQV | $42.63B | 13.9% | 31.5 | +52.32% |
| NateraNTRA | $41.83B | -8.5% | — | +54.26% |
| Agilent TechnologiesA | $48.75B | 24.5% | 34.3 | +54.18% |
| Mettler-Toledo InternationalMTD | $34.07B | 27.8% | 37.2 | +66.04% |
| IDEXX LaboratoriesIDXX | $55.2B | 32.5% | 46.8 | +30.53% |
| Labcorp HoldingsLH | $30.24B | 11.2% | 30.5 | +47.06% |
Same industry or related industries, similar size. Compare IQVIA Holdings with its competitors · Full profile
